Therapeutics News and Research

RSS

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

Volunteering for peer counseling programs benefits people with lupus

Conventional wisdom has it that volunteering is good for you, and a study at Hospital for Special Surgery shows that to be true for people with lupus volunteering in a peer support and education program.

23 Oct 2018

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Educational initiatives needed to improve knowledge about biosimilars in oncology

Biological medicines are responsible for some of the most promising innovations in cancer treatment, including immunotherapy, targeted drugs and vaccines - but they are also expensive.

22 Oct 2018

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

While it is widely shown that possessing the ApoE4 gene is the major genetic risk factor of Alzheimer's disease, not all ApoE4 carriers develop AD.

20 Oct 2018

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Some bacterial pathogens, including those that cause strep throat and pneumonia, are able to create the components necessary to replicate their DNA without the usually required metal ions.

19 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

URMC researchers discover new approach to deliver therapeutics to the brain

Researchers at the University of Rochester Medical Center have discovered a potentially new approach to deliver therapeutics more effectively to the brain. The research could have implications for the treatment of a wide range of diseases, including Alzheimer's, Parkinson's, ALS, and brain cancer.

19 Oct 2018

Mice study shows antibiotics are not always necessary to cure sepsis

Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice.

17 Oct 2018

Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis

According to an online survey, although healthcare providers report sharing crucial information on bacterial vaginosis with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect.

16 Oct 2018

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.

15 Oct 2018

Researchers demonstrate integrated technique to control production of cell therapeutics

Researchers have demonstrated an integrated technique for monitoring specific biomolecules - such as growth factors - that could indicate the health of living cell cultures produced for the burgeoning field of cell-based therapeutics.

15 Oct 2018

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.

15 Oct 2018

Researchers develop two-pronged approach for targeting Ebola virus

In a new study researchers have developed a two-pronged approach for targeting Ebola virus infection using linked nucleic acid (LNA) antisense oligonucleotides (ASOs)designed to interfere both genes essential for translation of Ebola virus genes and to block production of an intracellular human protein needed for the virus to enter cells.

12 Oct 2018

Synspira’s abstracts accepted for presentation at the 32nd Annual NACFC

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abstracts have been accepted for presentation at the 32nd Annual North American Cystic Fibrosis Conference, occurring October 18-20 in Denver, CO.

12 Oct 2018

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

11 Oct 2018

Researchers unravel fresh clues as to how kidney stones form

Kidney stones--solid, pebble-like grit that forms when too much of certain minerals like calcium are in the urine--can strike men, women, and increasingly, children, and the presence and pain of stones afflicts more than 12 percent of the world's population.

11 Oct 2018

Therapeutics News and Research

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Volunteering for peer counseling programs benefits people with lupus

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Educational initiatives needed to improve knowledge about biosimilars in oncology

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

ApoE4 gene linked with chronic inflammation increases risk for Alzheimer's disease

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

URMC researchers discover new approach to deliver therapeutics to the brain

Mice study shows antibiotics are not always necessary to cure sepsis

Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Researchers demonstrate integrated technique to control production of cell therapeutics

Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia

Researchers develop two-pronged approach for targeting Ebola virus

Synspira’s abstracts accepted for presentation at the 32nd Annual NACFC

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Researchers unravel fresh clues as to how kidney stones form

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News